European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma.


Journal

The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553

Informations de publication

Date de publication:
12 06 2023
Historique:
received: 07 10 2022
revised: 23 12 2022
accepted: 02 04 2023
medline: 14 6 2023
pubmed: 3 5 2023
entrez: 3 5 2023
Statut: ppublish

Résumé

Skin metastases are an important co-morbidity in melanoma. Despite broad adoption, electrochemotherapy implementation is hindered by a lack of treatment indications, uncertainty regarding procedural aspects, and the absence of quality indicators. An expert consensus may harmonize the approach among centres and facilitate comparison with other therapies. An interdisciplinary panel was recruited for a three-round e-Delphi survey. A literature-based 113-item questionnaire was proposed to 160 professionals from 53 European centres. Participants rated each item for relevance and degree of agreement on a five-point Likert scale, and received anonymous controlled feedback to allow revision. The items that reached concordant agreement in two successive iterations were included in the final consensus list. In the third round, quality indicator benchmarks were defined using a real-time Delphi method. The initial working group included 122 respondents, of whom 100 (82 per cent) completed the first round, thus qualifying for inclusion in the expert panel (49 surgeons, 29 dermatologists, 15 medical oncologists, three radiotherapists, two nurse specialists, two clinician scientists). The completion rate was 97 per cent (97 of 100) and 93 per cent (90 of 97) in the second and third rounds respectively. The final consensus list included 54 statements with benchmarks (treatment indications, (37); procedural aspects, (1); quality indicators, (16)). An expert panel achieved consensus on the use of electrochemotherapy in melanoma, with a core set of statements providing general direction to electrochemotherapy users to refine indications, align clinical practices, and promote quality assurance programmes and local audits. The residual controversial topics set future research priorities to improve patient care. Electrochemotherapy is an effective locoregional therapy for skin metastases from melanoma, a problem faced by almost half of patients with metastatic disease. The lack of comparative studies and the heterogeneity of its clinical application among centres make it challenging to support consistent, evidence-based recommendations. To address this unmet need, a three-round online survey was conducted to establish a consensus on treatment indications, standard operating procedures, and quality indicators. In the survey, a panel of 100 European melanoma experts agreed on 56 statements that can be used to improve patient selection, homogenize treatment application, and monitor outcomes.

Sections du résumé

BACKGROUND
Skin metastases are an important co-morbidity in melanoma. Despite broad adoption, electrochemotherapy implementation is hindered by a lack of treatment indications, uncertainty regarding procedural aspects, and the absence of quality indicators. An expert consensus may harmonize the approach among centres and facilitate comparison with other therapies.
METHODS
An interdisciplinary panel was recruited for a three-round e-Delphi survey. A literature-based 113-item questionnaire was proposed to 160 professionals from 53 European centres. Participants rated each item for relevance and degree of agreement on a five-point Likert scale, and received anonymous controlled feedback to allow revision. The items that reached concordant agreement in two successive iterations were included in the final consensus list. In the third round, quality indicator benchmarks were defined using a real-time Delphi method.
RESULTS
The initial working group included 122 respondents, of whom 100 (82 per cent) completed the first round, thus qualifying for inclusion in the expert panel (49 surgeons, 29 dermatologists, 15 medical oncologists, three radiotherapists, two nurse specialists, two clinician scientists). The completion rate was 97 per cent (97 of 100) and 93 per cent (90 of 97) in the second and third rounds respectively. The final consensus list included 54 statements with benchmarks (treatment indications, (37); procedural aspects, (1); quality indicators, (16)).
CONCLUSION
An expert panel achieved consensus on the use of electrochemotherapy in melanoma, with a core set of statements providing general direction to electrochemotherapy users to refine indications, align clinical practices, and promote quality assurance programmes and local audits. The residual controversial topics set future research priorities to improve patient care.
Electrochemotherapy is an effective locoregional therapy for skin metastases from melanoma, a problem faced by almost half of patients with metastatic disease. The lack of comparative studies and the heterogeneity of its clinical application among centres make it challenging to support consistent, evidence-based recommendations. To address this unmet need, a three-round online survey was conducted to establish a consensus on treatment indications, standard operating procedures, and quality indicators. In the survey, a panel of 100 European melanoma experts agreed on 56 statements that can be used to improve patient selection, homogenize treatment application, and monitor outcomes.

Autres résumés

Type: plain-language-summary (eng)
Electrochemotherapy is an effective locoregional therapy for skin metastases from melanoma, a problem faced by almost half of patients with metastatic disease. The lack of comparative studies and the heterogeneity of its clinical application among centres make it challenging to support consistent, evidence-based recommendations. To address this unmet need, a three-round online survey was conducted to establish a consensus on treatment indications, standard operating procedures, and quality indicators. In the survey, a panel of 100 European melanoma experts agreed on 56 statements that can be used to improve patient selection, homogenize treatment application, and monitor outcomes.

Identifiants

pubmed: 37131298
pii: 7148599
doi: 10.1093/bjs/znad105
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

818-830

Subventions

Organisme : IGEA
Organisme : Piccoli Punti Onlus

Investigateurs

Mauro Alaibac (M)
Paolo Amerio (P)
Paolo Ascierto (P)
Giuseppe Azzarello (G)
Susanne Baier (S)
Eszter Baltas (E)
Joana Bartolo (J)
Falk Bechara (F)
Francesco Bellucci (F)
Giulia Bertino (G)
Antonio Bonadies (A)
Lorenzo Borgognoni (L)
Mike Bourke (M)
Alison Bracken (A)
Paola Brandani (P)
Matteo Brizio (M)
Carlo Cabula (C)
Sarah Calabrese (S)
Luca G Campana (LG)
Corrado Caracò (C)
Cinzia Carriere (C)
Sara Carvalhal (S)
Vanna Chiarion (V)
James Clover (J)
Piero Covarelli (P)
Pietro Curatolo (P)
Corrado Dalio (C)
Nicola di Meo (N)
Gianluca Di Monta (G)
Karin-A Dietrich (KA)
Klaus Eisendle (K)
Tommaso Fabrizio (T)
Fabrizio Fantini (F)
Victor Farricha (V)
Virginia Ferraresi (V)
Francesco Ferraù (F)
Maria T Fierro (MT)
Sara Galuppo (S)
Alessandro Gatti (A)
Julie Gehl (J)
Till Geimer (T)
Gianni Gerlini (G)
Chiara Gregorelli (C)
Ales Groselj (A)
Michele Guida (M)
Massimo Guidoboni (M)
Jürg Hafner (J)
Schapoor Hessam (S)
Jackie Hodgetts (J)
Jason Kelly (J)
Erika Kis (E)
Christian Kunte (C)
Alastair McKenzie Ross (AM)
Giorgio Manca (G)
Mario Mndalà (M)
Ugo Marone (U)
Paolo Matteucci (P)
Andrea Maurichi (A)
Simone Mocellin (S)
David Moreno-Ramirez (D)
David Mowatt (D)
Michael Mühlstädt (M)
Tobias Muir (T)
Thomas Mussack (T)
Janja Ocvirk (J)
Joy Odili (J)
Judit Oláh (J)
Antonio Orlando (A)
Gaetano Pascoletti (G)
Roberto Patuzzo (R)
Howard Peach (H)
Dario Piazzalunga (D)
Camillo Porta (C)
Barry Powell (B)
Pietro Quaglino (P)
Simone Ribero (S)
Laura Ridolfi (L)
Rodrigo Oom (R)
Carlo R Rossi (CR)
Ernesto Rossi (E)
Roberta Rotunno (R)
Piotr Rutkowski (P)
Giusy Scandurra (G)
Matteo Sepulcri (M)
Gregor Sersa (G)
Serena Sestini (S)
Marko Snoj (M)
Declan Soden (D)
Nicola Solari (N)
Pier F Soma (PF)
Luca Stingeni (L)
Davide Strippoli (D)
Andrew Sykes (A)
Francesca Tauceri (F)
Alessandro Testori (A)
Bèatrice Trigona (B)
Angelo Turoldo (A)
Sara Valpione (S)
Antonella Vecchiato (A)
Marcin Zdzienicki (M)

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Luca G Campana (LG)

Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK.

Sofia Farronato (S)

Institute of General Practice, College of Health Care Professions Claudiana, Bolzano/Bozen, Italy.

Jackie Hodgetts (J)

Medical Oncology, Christie NHS Foundation Trust, Manchester, UK.

Joy Odili (J)

Department of Plastic Surgery, St George's Hospital, London, UK.

Antonella Vecchiato (A)

Melanoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.

Alison Bracken (A)

Cork Cancer Research Centre, Cork, Ireland.

Susanne Baier (S)

Medical Oncology Unit, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy.

Falk G Bechara (FG)

Department of Dermatology, Venereology, and Allergology, St Josef Hospital, Ruhr University, Bochum, Germany.

Lorenzo Borgognoni (L)

Plastic and Reconstructive Surgery Unit, Department of Surgery, Santa Maria Annunziata Hospital, Florence, Italy.

Corrado Caracò (C)

Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.

Sara Carvalhal (S)

Melanoma and Sarcoma Unit, Department of Surgery, Portuguese Institute of Oncology, Lisbon, Portugal.

Piero Covarelli (P)

Department of Surgery and Medicine, University of Perugia, Perugia, Italy.

James Clover (J)

Cork Cancer Research Centre, Cork, Ireland.

Klaus Eisendle (K)

Teaching Department of Dermatology, Central Hospital Bolzano, Bozen/Bolzano, Italy.

Fabrizio Fantini (F)

Dermatology Unit, Azienda Ospedaliera 'A. Manzoni', Lecco, Italy.

Maria Teresa Fierro (MT)

Department of Dermatology, University of Turin, Turin, Italy.

Victor Farricha (V)

Melanoma and Sarcoma Unit, Department of Surgery, Portuguese Institute of Oncology, Lisbon, Portugal.

Chiara Gregorelli (C)

Department of Plastic Surgery, ASST Spedali Civili, Brescia, Italy.

Jürg Hafner (J)

Department of Dermatology, University of Zurich, Zurich, Switzerland.

Christian Kunte (C)

Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany.
Department of Dermatosurgery and Dermatology, Artemed Hospital, Munich, Germany.

Gianni Gerlini (G)

Plastic and Reconstructive Surgery Unit, Department of Surgery, Santa Maria Annunziata Hospital, Florence, Italy.

Schapoor Hessam (S)

Department of Dermatology, Venereology, and Allergology, St Josef Hospital, Ruhr University, Bochum, Germany.

Mario Mandalà (M)

Unit of Medical Oncology, Department of Surgery and Medicine, University of Perugia, Perugia, Italy.

Dario Piazzalunga (D)

General Surgery Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Pietro Quaglino (P)

Department of Dermatology, University of Turin, Turin, Italy.

Marko Snoj (M)

Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Alastair Mackenzie Ross (AM)

Department of Plastic Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Béatrice Trigona (B)

Dermatosurgery Unit, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

David Moreno-Ramirez (D)

Dermatology Unit, Virgen Macarena University Hospital, Seville, Spain.

Francesca Tauceri (F)

General and Oncological Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.

Howard Peach (H)

Department of Plastic and Reconstructive Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Piotr Rutkowski (P)

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Centre, Warsaw, Poland.

Tobian Muir (T)

Department of Plastic and Reconstructive Surgery, James Cook University Hospital, Middlesbrough, UK.

Francesca de Terlizzi (F)

IGEA, Clinical Biophysics Department, Modena, Italy.

Roberto Patuzzo (R)

Melanoma Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Michael Mühlstädt (M)

Dermatosurgery Unit, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Karin-Almut Dietrich (KA)

Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany.

Thomas Mussack (T)

Department of General and Abdominal Surgery, Munich South Surgical Hospital, Munich, Germany.

Paolo Matteucci (P)

Department of Plastic and Reconstructive Surgery, Hull University Teaching Hospitals NHS Trust, Hull, UK.

Erika Kis (E)

Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.

Paolo Ascierto (P)

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, INT IRCCS Fondazione 'G. Pascale', Naples, Italy.

Gregor Sersa (G)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Sara Valpione (S)

Medical Oncology, Christie NHS Foundation Trust, Manchester, UK.
Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH